[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![SchwabNetwork Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::872519322077470721.png) Schwab Network [@SchwabNetwork](/creator/twitter/SchwabNetwork) on x 74.5K followers
Created: 2025-06-16 16:49:08 UTC

$SRPT plunged nearly 45%, hitting its lowest level since mid-2016, after a second death was linked to its Elevidys gene therapy. 

Sarepta Therapeutics will pause dosing in a Phase X study involving non-ambulatory patients with Duchenne muscular dystrophy (DMD). It also halted shipments of Elevidys for patients who can't walk.

Sarepta suspended its 2025 revenue guidance.

![](https://pbs.twimg.com/media/GtlFmZVWAAAzJ5i.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1934654485638341099/c:line.svg)

**Related Topics**
[sarepta therapeutics](/topic/sarepta-therapeutics)
[$srpt](/topic/$srpt)
[sarepta therapeutics inc](/topic/sarepta-therapeutics-inc)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/SchwabNetwork/status/1934654485638341099)